ARCA biopharma Inc

Research ARCA biopharma Inc (ORKA) on Bullrun: market cap USD 5.58B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerORKA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 5.58B
• Financial periodFY2025
• Net income-USD 105.43M
• Free cash flow-USD 88.42M

Valuation Snapshot

latest market cap is USD 5.58B.

About ARCA biopharma Inc

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.

Frequently asked questions

What is ARCA biopharma Inc's market cap?

ARCA biopharma Inc's market capitalization is USD 5.58B.

What does ARCA biopharma Inc do?

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.